Cubist Systematic Strategies, LLC Albireo Pharma, Inc. Transaction History

Cubist Systematic Strategies, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$18.01 - $23.78 $88,789 - $117,235	4,930 Added 132.88%	8,640 $186,000
Q3 2022 Nov 14, 2022	BUY	$16.32 - $26.37 $60,547 - $97,832	3,710 New	3,710 $72,000
Q2 2022 Aug 15, 2022	SELL	$18.54 - $37.29 $203,476 - $409,257	-10,975 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$23.94 - $33.74 $239,543 - $337,602	10,006 Added 1032.61%	10,975 $327,000
Q4 2021 Feb 14, 2022	BUY	$21.19 - $31.29 $20,533 - $30,320	969 New	969 $23,000
Q4 2020 Feb 16, 2021	SELL	$31.56 - $42.16 $224,991 - $300,558	-7,129 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$23.19 - $41.61 $164,718 - $295,555	7,103 Added 27319.23%	7,129 $238,000
Q2 2020 Aug 14, 2020	SELL	$14.82 - $29.92 $121,953 - $246,211	-8,229 Reduced 99.69%	26 $1,000
Q1 2020 May 15, 2020	BUY	$11.67 - $27.23 $96,335 - $224,783	8,255 New	8,255 $135,000
Q4 2019 Feb 14, 2020	SELL	$16.92 - $28.96 $7,021 - $12,018	-415 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$20.0 - $31.88 $6,880 - $10,966	-344 Reduced 45.32%	415 $8,000
Q2 2019 Aug 14, 2019	BUY	$30.67 - $37.86 $23,278 - $28,735	759 New	759 $24,000

865

Ticker ALBO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,612,500
Description
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as we...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.